Dual Fenton Catalytic Nanoreactor for Integrative Type-I and Type-II Photodynamic Therapy Against Hypoxic Cancer Cells

Xiao Cui; Jinfeng Zhang; Yingpeng Wan; Fang Fang; Rui Chen; Dong Shen; Zhongming Huang; Shuang Tian; Yafang Xiao; Xiaozhen Li; Jipsa Chelora; Yanhong Liu; Wenjun Zhang; Chun-Sing Lee

doi:10.1021/acsabm.9b00456

Author(s)

Related Research Unit(s)

Detail(s)

Original language	English
Pages (from-to)	3854−3860
Journal / Publication	ACS Applied Bio Materials
Volume	2
Issue number	9
Online published	21 Aug 2019
Publication status	Published - 16 Sept 2019

Link(s)

DOI	DOI https://doi.org/10.1021/acsabm.9b00456 Final Published version
	Check@CityULib
Link to Scopus	https://www.scopus.com/record/display.uri?eid=2-s2.0-85072649729&origin=recordpage
Permanent Link	https://scholars.cityu.edu.hk/en/publications/publication(f23dd04b-e1b4-4a8e-86a2-8b609298b46c).html

Abstract

Tumor hypoxia is a noteworthy impediment to effective photodynamic therapy (PDT), as it would sharply weaken the effectiveness of oxygen-dependent PDT. To enable effective PDT in both hypoxia as well as normoxia circumstances, here, we report a multifunctional nanoreactor (C₃N₄/MnO₂ NPs), which guarantees effective type-II PDT (oxygen-dependent) in hypoxia by in situ oxygen generation via the Fenton reaction. In addition, the C₃N₄/MnO₂ NPs can also be used for oxygen-independent type-I PDT by evolving the cytotoxic hydroxyl radical to reduce reliance on intracellular oxygen content. In vitro cytotoxicity assays made evident that the C₃N₄/MnO₂ NPs exhibit a much higher cancer-cell-killing ability than C₃N₄ NPs not only in normoxia but also in hypoxic circumstances. The smart integration of type-I and type-II PDT into the therapeutic nanoplatform enables effective PDT even though intracellular oxygen is not satisfactory.